FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904376503> ?p ?o ?g. }

• W2904376503 endingPage "8" @default.
• W2904376503 startingPage "1" @default.
• W2904376503 abstract "Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor beta1, and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia Shosaku Nomura, Tomoki Ito, Atsushi Satake, Kazuyoshi Ishii First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan Background: The outcome for chronic myelogenous leukemia (CML) patients presented in the chronic phase has changed dramatically since the introduction of tyrosine kinase inhibitor (TKI) therapy. Notably, an increased incidence of large granular lymphocytes (LGLs), which is related to immunological conditions, appears to be predictive of a favorable outcome for dasatinib therapy. We therefore examined the immunological characteristics of CML patients during dasatinib therapy by determining the plasma concentrations of five different biomarkers. Methods: The plasma levels of biomarkers, specifically interleukin-6, platelet-derived microparticles (PDMPs), soluble vascular cell adhesion molecule 1 (sVCAM-1), transforming growth factor (TGF) β1, and soluble cytotoxic T lymphocyte-associated antigen-4 (sCTLA-4), were measured by ELISA at baseline and after 2 and 6 months of TKI treatment. The incidence of LGLs was estimated by microscopic examination. Results: The levels of PDMPs, sVCAM-1, and TGFβ1 were significantly elevated in patients with CML. Dasatinib treatment was associated with a significant reduction in the levels of these markers and with an increased incidence of LGLs compared with imatinib or nilotinib treatment. In addition, an increased incidence of LGLs was significantly correlated with a decreased sCTLA-4 level during dasatinib therapy. Conclusion: The assessment of the levels of specific biomarkers may be beneficial to understand the immunological conditions of patients with CML during dasatinib treatment. Keywords: CML, TKI, LGL, PDMP, TGFβ1, sCTLA-4" @default.
• W2904376503 created "2018-12-22" @default.
• W2904376503 creator A5002284882 @default.
• W2904376503 creator A5033178635 @default.
• W2904376503 creator A5066359544 @default.
• W2904376503 creator A5067399580 @default.
• W2904376503 date "2018-12-01" @default.
• W2904376503 modified "2023-10-16" @default.
• W2904376503 title "Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β₁, and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia" @default.
• W2904376503 cites W1556295451 @default.
• W2904376503 cites W1566390556 @default.
• W2904376503 cites W1850586 @default.
• W2904376503 cites W1915526309 @default.
• W2904376503 cites W1935158033 @default.
• W2904376503 cites W1954967105 @default.
• W2904376503 cites W1966066618 @default.
• W2904376503 cites W1971749359 @default.
• W2904376503 cites W1975605578 @default.
• W2904376503 cites W1978663734 @default.
• W2904376503 cites W1983284248 @default.
• W2904376503 cites W1986139301 @default.
• W2904376503 cites W1991464577 @default.
• W2904376503 cites W1998593414 @default.
• W2904376503 cites W2009972868 @default.
• W2904376503 cites W2012264906 @default.
• W2904376503 cites W2012780133 @default.
• W2904376503 cites W2014316424 @default.
• W2904376503 cites W2014839361 @default.
• W2904376503 cites W2032784036 @default.
• W2904376503 cites W2054543813 @default.
• W2904376503 cites W2058216377 @default.
• W2904376503 cites W2073035156 @default.
• W2904376503 cites W2117893664 @default.
• W2904376503 cites W2139962842 @default.
• W2904376503 cites W2141700184 @default.
• W2904376503 cites W2149123553 @default.
• W2904376503 cites W2158196950 @default.
• W2904376503 cites W2158460758 @default.
• W2904376503 cites W2162819001 @default.
• W2904376503 cites W2166654361 @default.
• W2904376503 cites W2167357790 @default.
• W2904376503 cites W2310036617 @default.
• W2904376503 cites W2418316406 @default.
• W2904376503 cites W2788900104 @default.
• W2904376503 cites W2791438625 @default.
• W2904376503 cites W288652962 @default.
• W2904376503 cites W4211076773 @default.
• W2904376503 cites W82906902 @default.
• W2904376503 doi "https://doi.org/10.2147/jbm.s187005" @default.
• W2904376503 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6305157" @default.
• W2904376503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30588140" @default.
• W2904376503 hasPublicationYear "2018" @default.
• W2904376503 type Work @default.
• W2904376503 sameAs 2904376503 @default.
• W2904376503 citedByCount "4" @default.
• W2904376503 countsByYear W29043765032019 @default.
• W2904376503 countsByYear W29043765032023 @default.
• W2904376503 crossrefType "journal-article" @default.
• W2904376503 hasAuthorship W2904376503A5002284882 @default.
• W2904376503 hasAuthorship W2904376503A5033178635 @default.
• W2904376503 hasAuthorship W2904376503A5066359544 @default.
• W2904376503 hasAuthorship W2904376503A5067399580 @default.
• W2904376503 hasBestOaLocation W29043765031 @default.
• W2904376503 hasConcept C126322002 @default.
• W2904376503 hasConcept C143998085 @default.
• W2904376503 hasConcept C154317977 @default.
• W2904376503 hasConcept C185592680 @default.
• W2904376503 hasConcept C202751555 @default.
• W2904376503 hasConcept C203014093 @default.
• W2904376503 hasConcept C2776960273 @default.
• W2904376503 hasConcept C2777583451 @default.
• W2904376503 hasConcept C2777761686 @default.
• W2904376503 hasConcept C2778461978 @default.
• W2904376503 hasConcept C2778729363 @default.
• W2904376503 hasConcept C2779536868 @default.
• W2904376503 hasConcept C55493867 @default.
• W2904376503 hasConcept C71924100 @default.
• W2904376503 hasConcept C90924648 @default.
• W2904376503 hasConceptScore W2904376503C126322002 @default.
• W2904376503 hasConceptScore W2904376503C143998085 @default.
• W2904376503 hasConceptScore W2904376503C154317977 @default.
• W2904376503 hasConceptScore W2904376503C185592680 @default.
• W2904376503 hasConceptScore W2904376503C202751555 @default.
• W2904376503 hasConceptScore W2904376503C203014093 @default.
• W2904376503 hasConceptScore W2904376503C2776960273 @default.
• W2904376503 hasConceptScore W2904376503C2777583451 @default.
• W2904376503 hasConceptScore W2904376503C2777761686 @default.
• W2904376503 hasConceptScore W2904376503C2778461978 @default.
• W2904376503 hasConceptScore W2904376503C2778729363 @default.
• W2904376503 hasConceptScore W2904376503C2779536868 @default.
• W2904376503 hasConceptScore W2904376503C55493867 @default.
• W2904376503 hasConceptScore W2904376503C71924100 @default.
• W2904376503 hasConceptScore W2904376503C90924648 @default.
• W2904376503 hasLocation W29043765031 @default.
• W2904376503 hasLocation W29043765032 @default.
• W2904376503 hasLocation W29043765033 @default.
• W2904376503 hasLocation W29043765034 @default.
• W2904376503 hasOpenAccess W2904376503 @default.

• next